FDA Cites Manufacturing Issues for Cytisinicline - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.

  • By

  • Kathryn Wighton

  • June 22, 2026

  • 3 min

Share

Clinical Report: FDA Cites Manufacturing Issues for Cytisinicline

Overview

The FDA issued a Complete Response Letter for cytisinicline, citing manufacturing issues at a third-party facility but found no deficiencies in clinical efficacy or safety. Achieve Life Sciences plans to resubmit the New Drug Application in late 2026.

Background

Cytisinicline is a plant-derived compound under development for smoking cessation. The FDA's Complete Response Letter highlights manufacturing compliance issues identified during an inspection.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • The FDA's Complete Response Letter cited manufacturing-related observations at a third-party facility.
  • No deficiencies were identified related to the clinical efficacy or safety of cytisinicline.
  • Achieve Life Sciences plans to resubmit the New Drug Application in Q4 2026.
  • The drug has received FDA Breakthrough Therapy designation for e-cigarette cessation.

Clinical Implications

Healthcare professionals should be aware of the regulatory challenges that can affect the availability of new smoking cessation therapies.

Conclusion

The FDA's feedback provides a pathway for Achieve Life Sciences to address manufacturing issues.

Related Resources & Content

  1. Achieve Life Sciences, Source, 2026 -- FDA Cites Manufacturing Issues for Cytisinicline
  2. The ASCO Post — Concerns About Safety of Generic Oncology Drugs Made in Developing Countries
  3. Open Forum Infectious Diseases — Stability and Recovery Assessment of Crushed 150-mg Omadacycline Tablets Mixed with Food or Water for Nasogastric Tube Administration
  4. The Journal of Infectious Diseases — Production of Clostridioides difficile Spores for Use in Human Volunteer Infection Studies
  5. conexiant — FDA Monthly Preview: Key June Decisions to Watch
  6. VA/DoD Clinical Practice Guideline for Management of Stroke Rehabilitation
  7. WHO Tobacco Cessation Clinical Treatment Guideline 2024
  8. NICE guideline NG209
  9. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial - PubMed
  10. Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial | Trials | JAMA Internal Medicine | JAMA Network
  11. Cytisinicline for Vaping Cessation in Adults Using Nicotine E-Cigarettes: The ORCA-V1 Randomized Clinical Trial - PMC
  12. Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates :: Achieve Life Sciences, Inc. (ACHV)

Original Source(s)

FDA Cites Manufacturing Issues for Cytisinicline

  • by Kathryn Wighton

  • June 22, 2026

Related Content

FDA revises monitoring for SCLC therapy

Initial monitoring decreases from 22 to 24 hours to 6 to 8 hours from the start of the first 2 infusions.

Screening Eligibility and Survival Among Patients With Lung Cancer in Korea

STAT6 may aid diagnosis of giant pulmonary SFT

Immunohistochemical testing confirmed a rare tumor despite low-grade histology, extensive local involvement, and suspected liver metastasis.